Clinical trials Brief October 22, 2026, 10:09 AM ET

Sanofi registers Phase 3 trial of combination SARS-CoV-2 and influenza vaccine in older adults

The study, led by Sanofi, plans to enroll an estimated 6000 participants aged 60 and older to assess the safety and immunogenicity of a combined SARS-CoV-2 recombinant spike and high-dose inactivated influenza vaccine with Matrix-M adjuvant. It is planned to begin on November 9, 2026, with primary completion expected on December 28, 2027.

Primary source

ClinicalTrials.gov registry record, October 22, 2026

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

Read the source: Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation